Genedata, a leading provider of advanced software solutions for biopharmaceutical R&D, today announced Genedata Expressionist® 12.0—the latest version of the market-leading enterprise software solution offering integrated data management, processing, analysis, and reporting for mass spectrometry-based characterization of biotherapeutics and related applications in proteomics and metabolomics.
Built on an open and flexible client-server architecture, Genedata Expressionist handles large and complex experimental data sets from all MS instrument vendors and technology platforms. Customizable workflows enable full automation and fast and flexible implementation of diverse experimental approaches; in particular, multi-attribute methods (MAM). Harmonization of data analysis processes and integrated data- and project-management streamlines methods and increases productivity and analysis result quality across enterprises.
GxP-compliance features and full integration into the Genedata Biopharma Platform for the capture, integration, and organization of heterogeneous data throughout the entire biopharma R&D process, make Genedata Expressionist the software of choice for MS data processing in complex collaborative projects.
Developed in close collaboration with leading partners in the biopharma industry, the latest version of Genedata Expressionist offers numerous improvements including:
Intelligent automation for efficient processing of large data sets
In alignment with the Genedata vision of completely automating data processes from raw data to reporting, Genedata Expressionist 12.0 sets a new standard for batch processing of MS data. Metadata can now be used to directly apply specific parameters to individual data sets, offering complete control over each experiment. As a result, automation with Genedata Expressionist 12.0 not only ensures enterprise-wide process harmonization and boosts productivity by eliminating laborious manual intervention, but also offers an exquisite level of control during processing.
Optional cloud deployment
In addition to on-premises installations, Genedata Expressionist can now be deployed in cloud environments such as Microsoft Azure (MS Azure) and Amazon Web Services (AWS). These options increase ease of access to the Genedata Expressionist enterprise platform and provide full scalability in terms of processing resources.
Personalizable interface for improved usability
Genedata Expressionist 12.0 comes with a completely redesigned user interface presenting all relevant information at a glance. Personalized layouts can be saved and applied to any data set, enabling users to configure data displays according to their individual needs—making for more convenient and faster data review and curation, and ultimately leading to better decision-making.
“With this latest release of Genedata Expressionist we have reached another important milestone on the path to complete automation of biopharmaceutical characterization workflows,” commented Dr. Othmar Pfannes, CEO of Genedata. “The rapid adoption of Genedata Expressionist across the whole R&D process—from bioanalytical labs in discovery to bioprocess development and even in manufacturing environments—is proof of the great value that our innovative enterprise solution brings to the biopharma industry. We remain committed to investing further significant resources to help our clients to bring innovative biotherapeutics of the highest quality to the market as quickly and as economically as possible.”
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI from their R&D. Founded in 1997, Genedata is headquartered in Switzerland and has offices in Germany, the UK, Japan, and the US.
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.